Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2026)
Denali Therapeutics' (DNLI) quarterly Return on Capital Employed came in at 49.95% in Q1 2026, down 810.0% year-on-year from 7.04% in Q1 2025, and up 9.88% on a QoQ basis from 55.43% in Q4 2025.
Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 9 years of Return on Capital Employed data on file, last reported at 49.95% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 810.0% year-over-year to 49.95% in Q1 2026; TTM through Mar 2026 was 49.95%, a 810.0% decrease from a year earlier, with the FY2025 full-year figure at 47.83%, down 588.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 49.95%, up from 55.43% in the prior quarter.
- Over the last five years, Return on Capital Employed for DNLI reached as high as 12.67% in Q2 2023 and fell as low as 55.43% in Q4 2025.
- Historically, Return on Capital Employed has averaged 34.06% across 5 years, with a median of 34.77% in 2022.
- Across the five-year window, Return on Capital Employed sank 3653 bps in 2022 and soared 2278 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 34.77% in 2022, then soared by 49 bps to 17.6% in 2023, then tumbled by 111 bps to 37.15% in 2024, then plunged by 49 bps to 55.43% in 2025, then rose by 10 bps to 49.95% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 49.95% in Q1 2026, 55.43% in Q4 2025, and 53.67% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Denali Therapeutics | 4.37 Bn | 4.37 Bn | - | -49.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.95% |
| Dec 31, 2025 | -55.43% |
| Sep 30, 2025 | -53.67% |
| Jun 30, 2025 | -47.31% |
| Mar 31, 2025 | -41.86% |
| Dec 31, 2024 | -37.15% |
| Sep 30, 2024 | -35.23% |
| Jun 30, 2024 | -32.76% |
| Mar 31, 2024 | -15.07% |
| Dec 31, 2023 | -17.60% |
| Sep 30, 2023 | -14.12% |
| Jun 30, 2023 | -12.67% |
| Mar 31, 2023 | -37.85% |
| Dec 31, 2022 | -34.77% |
| Sep 30, 2022 | -34.75% |
| Jun 30, 2022 | -30.32% |
| Mar 31, 2022 | -28.50% |
| Dec 31, 2021 | -28.20% |
| Sep 30, 2021 | 1.79% |
| Jun 30, 2021 | 3.45% |